Neurocrine

Webcast Alert: Neurocrine Announces 1Q08 Financial Results

SAN DIEGO, April 30 /PRNewswire-FirstCall/ -- Neurocrine Biosciences (Nasdaq: NBIX ) announces the following Webcast: What: Neurocrine Announces 1Q08 Financial Results When: Wednesday, April 30, 2008 at 5:00PM ET / 2:00PM PT Where: http://www.videonewswire.com/event.asp?id...

Sundia MediTech Appoints Dr. Chen Chen as Senior VP of Chemistry

... announced today that Dr. Chen Chen has been appointed Senior Vice President of Chemistry Services. Prior to joining Sundia, Dr. Chen worked at neurocrine Biosciences, a drug discovery and development company in San Diego, USA for 15 years, from a staff scientist to Senior Director of Medicinal Chemistry...

Neurocrine Announces Full Year Results from 603 Study (Petal Study) of Elagolix for Treatment of Endometriosis Pain

...ious Positive Findings on Efficacy and Safety neurocrine to Present These Additional Study Results at Deuts... SAN DIEGO, May 18 /PRNewswire-FirstCall/ -- neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announce...on bone mineral density (BMD), was met at Week 24. neurocrine now has confirmation of a favorable bone safety pr...

Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2009 Financial Results

... SAN DIEGO, April 29 /PRNewswire-FirstCall/ -- neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced toda...the Nasdaq market closes on Tuesday, May 5, 2009. neurocrine will then host a live conference call and webcast ...lease contact the Investor Relations Department at neurocrine Biosciences at (858) 617-7600. A replay of the Co...

Neurocrine Biosciences Reports Fourth Quarter and Year-End 2008 Results

... SAN DIEGO, Feb. 3 /PRNewswire-FirstCall/ -- neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announce...ments," said Kevin C. Gorman, President and CEO of neurocrine Biosciences. 2009 Financial Guidance E...e advancing its lead programs through development. neurocrine scientists continue to build the Company's pipelin...

Neurocrine Announces Closing of $109 Million Sale and Leaseback Agreement for its Real Estate Assets

... SAN DIEGO, Dec. 6 /PRNewswire-FirstCall/ -- neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today...eal estate assets. Total consideration received by neurocrine for the properties was $109 million. Concurrently ...quarters for a 12 year term, with renewal options. neurocrine also has certain options under the lease to repurc...

Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference

...2007 SAN DIEGO, Nov. 5 /PRNewswire-FirstCall/ -- neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that neurocrine Biosciences will present at the CIBC World Markets...lease contact the Investor Relations Department at neurocrine Biosciences at (858) 617-7600. Viewers are encoura...

Ambien and the Other Insomnia Drugs

...atient population is being treated with drug therapy. He also predicts that the market would grow up to 30% this year. Indiplon, created by Pfizer and neurocrine Biosciences is expected to hit the markets this autumn but their approval by the Food & Drug Administration is pending. The drug will come in two...

Neurocrine in Medical Technology

Neurocrine Biosciences Presents Elagolix Data

... SAN DIEGO, June 16 /PRNewswire-FirstCall/ -- neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced toda...unity," said Chris O'Brien, Chief Medical Officer, neurocrine Biosciences. "An orally active gonadotropin releas...x dose and regimen for the Phase III trials." neurocrine Biosciences also presented a preclinical study whi...

Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain

... SAN DIEGO, March 25 /PRNewswire-FirstCall/ -- neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announce...n Gorman, President and Chief Executive Officer of neurocrine Biosciences. "This Phase II study provides the in..." said Dr. Chris O'Brien, Chief Medical Officer of neurocrine Biosciences. "The decoupling of these exploratory...

invivodata Captures Symptom Relief Data in Endometriosis Trial

... neurocrine Biosciences Demonstrates Rapid and Significant Pai...ture important secondary efficacy endpoint data in neurocrine Biosciences' (Nasdaq: NBIX ) PETAL study, a Phase..." said Chris O'Brien, MD, Chief Medical Officer at neurocrine Biosciences. "invivodata's process for designing a...

Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis

... PT SAN DIEGO, Sept. 2 /PRNewswire-FirstCall/ -- neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced...ometriosis symptom reduction without bone loss." neurocrine Biosciences would like to thank the patients and t...lease contact the Investor Relations Department at neurocrine Biosciences at (858) 617-7600. A replay of the Con...

Neurocrine Biosciences Completes 'Petal Study' Treatment Phase for Endometriosis

...ITY SAN DIEGO, June 17 /PRNewswire-FirstCall/ -- neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today... over the upcoming weeks. As announced previously, neurocrine is on track to report this treatment phase topline...roductive and Urologic Drug Products at the FDA. neurocrine Biosciences, Inc. is a biopharmaceutical company f...

Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results

...rved most recently as Senior Vice President of Finance, Chief Financial Officer and Treasurer. Prior to Metabasis, he served as Director of Finance of neurocrine Biosciences, Inc., where he played an important role in Neurocrine's 1996 initial public offering. Prior to joining Neurocrine, Mr. Beck held financia...

Neurocrine Biosciences Reports First Quarter 2008 Results

... SAN DIEGO, April 30 /PRNewswire-FirstCall/ -- neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced...n, Ph.D., President and Chief Executive Officer of neurocrine Biosciences. "Our goals for the GnRH program are t...and will report on R & D progress throughout 2008. neurocrine scientists continue to supply Neurocrine's pipelin...

Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results

... SAN DIEGO, Feb. 5 /PRNewswire-FirstCall/ -- neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced... year," said Kevin C. Gorman, President and CEO of neurocrine Biosciences. Indiplon update On December 12, 2...e advancing its lead programs through development. neurocrine scientists continue to build the Company's pipelin...

Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia

... errors, charting deviations, and falling asleep unintentionally at work. neurocrine is developing indiplon for the treatment of insomnia. Indiplon was licensed...ended December 31, 2006 and Form 10-Q for the quarter ended March 31, 2007. neurocrine undertakes no obligation to update the statements contained in this press r...

Neurocrine in Biological News

OHSU turns innovations into commercial opportunities at record pace

...e previous year. The market value of equity OHSU owns in six startups whose shares are publicly traded Novacea, Inc.; Adherex Technologies Inc.; neurocrine Biosciences, Inc.; Orexigen Therapeutics, Inc.; StemCells, Inc. and Fonix Corporation reached $2.25 million at the end of the fiscal year, up from $1...

Neurocrine in Biological Technology

Webcast Alert: Neurocrine Biosciences Announces 2nd Quarter 2009 Earnings Results

SAN DIEGO, July 27 /PRNewswire-FirstCall/ -- Neurocrine Biosciences (Nasdaq: NBIX ) announces the following Webcast: What: Neurocrine Biosciences Webcast When: July 30, 2009 @ 8:30am EDT Where: http://www.videonewswire.com/event.asp?id=60921 H...

Webcast Alert: Neurocrine Announces 3Q 08 Financial Results

SAN DIEGO, Oct. 28 /PRNewswire-FirstCall/ -- Neurocrine Biosciences (Nasdaq: NBIX ) announces the following Webcast: What: Neurocrine Biosciences 3rd Quarter 2008 Financial Results When: October 28, 2008 @ 5 p.m. Eastern 2 p.m. Pacific Where: http://www.videonewswire.com/eve...

Neurocrine Biosciences Reports Second Quarter 2009 Results

... SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announce...ebcast Thursday, July 30, 2009 at 8:30 a.m. EDT neurocrine will hold a live conference call and webcast tomor...lease contact the Investor Relations Department at neurocrine Biosciences at (858) 617-7600. A replay of the con...

Elagolix Successful in Six Month Lilac Petal Study; Safety and Efficacy Confirmed in Patients With Endometriosis

... SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announce...ate," said Chris O'Brien, Chief Medical Officer of neurocrine Biosciences, "Most importantly, we find that the 2...x continued under double-blind conditions. neurocrine will discuss these clinical trial results as part ...

Neurocrine Biosciences Announces Conference Call and Webcast to Present Second Quarter 2009 Financial Results

... SAN DIEGO, July 23 /PRNewswire-FirstCall/ -- neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced toda...asdaq market closes on Wednesday, July 29, 2009. neurocrine will then host a live conference call and webcast...lease contact the Investor Relations Department at neurocrine Biosciences at (858) 617-7600. A replay of the Co...

Poniard Pharmaceuticals Appoints Gary A. Lyons to Board of Directors

...pects to expand his consulting arrangement as it moves forward with its commercialization and partnering activities. Gary has served as a Director of neurocrine Biosciences, Inc. since February 1993 and held various executive positions with Neurocrine, including President and Chief Executive Officer, from Febr...

New Report Just Published: World Prostate Cancer Therapeutics Market Report

... Astellas on Degarelix License for Prostate Cancer Treatment II-85 Protox Acquires PRX321 Cancer Program from US Public Health Service and neurocrine II-86 Astex Collaborates with CRT and Newcastle University for New Drug Discovery II-86 Miraculins and Duke University Enter into Collabor...

Neurocrine Biosciences to Present at the 8th Annual Needham Life Sciences Conference

... SAN DIEGO, June 4 /PRNewswire-FirstCall/ -- neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced toda...n Gorman, President and Chief Executive Officer of neurocrine Biosciences will be presenting at the 8th Annual N... announcement please contact Investor Relations at neurocrine Biosciences at (858) 617-7600. Viewers are encour...

Neurocrine Biosciences to Present at the Deutsche Bank 34th Annual Health Care Conference

... SAN DIEGO, May 11 /PRNewswire-FirstCall/ -- neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced toda...n Gorman, President and Chief Executive Officer of neurocrine Biosciences will be presenting at the Deutsche Ban...lease contact the Investor Relations Department at neurocrine Biosciences at (858) 617-7600. Viewers are encour...

Neurocrine Biosciences Reports First Quarter 2009 Results

... SAN DIEGO, May 5 /PRNewswire-FirstCall/ -- neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announce...n, Ph.D., President and Chief Executive Officer of neurocrine Biosciences. Pipeline Highlights G... the estimated 180 subjects have been randomized. neurocrine expects to have top-line data from this trial in t...